The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

The stock is down 3%, or $2.81, to $80.26 in premarket trading.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with ...

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated ...

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...